Immunocore’s Strong Growth Potential Justifies Buy Rating Despite Minor Revenue Adjustment
I'm PortAI, I can summarize articles.
Analyst Tyler Van Buren from TD Cowen maintains a Buy rating on Immunocore Holdings with a $60 price target, despite a minor revenue forecast adjustment for Kimmtrak in 2025. The positive outlook is based on Immunocore's third-quarter earnings report, projecting $405 million in revenue. H.C. Wainwright also reiterated a Buy rating with a $100 price target, indicating strong growth potential and a favorable investment opportunity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments